Toxicity to intravitreal melphalan in a patient with retinoblastoma

Objective: Description of melphalan’s toxicity in retinoblastoma treatment. Methods: Clinical case report. Results: We presented a case of unilateral retinoblastoma with vitreous seeding at diagnosis, in which the use of intravitreal melphalan produced many adverse reactions. Conclusions: Vitreous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Solaz-Ruiz, Marta Gema, Pérez, Lorena Azorín, Cauto-Picazo, Carlos, Barranco-González, Honorio, Pascual-Camps, Isabel, España-Gregori, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Romanian Society of Ophthalmology 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591425/
https://www.ncbi.nlm.nih.gov/pubmed/37876503
http://dx.doi.org/10.22336/rjo.2023.49
Descripción
Sumario:Objective: Description of melphalan’s toxicity in retinoblastoma treatment. Methods: Clinical case report. Results: We presented a case of unilateral retinoblastoma with vitreous seeding at diagnosis, in which the use of intravitreal melphalan produced many adverse reactions. Conclusions: Vitreous seedings have been one of the most important challenges in retinoblastoma treatment. Intravitreal melphalan has achieved the regression of vitreous seedings in a large percentage of cases. It is a safe treatment; however, it can produce toxicity, even with the standard dose of 20-30 µg, which has been poorly documented. Exhaustive follow-up of patients is recommended for an early diagnosis of possible adverse effects. Abbreviations: OS = left eye, RI = magnetic resonance imaging, OCT = optical coherence tomography

Ejemplares similares